Sign Up for a Free Account
  • Updated 10.06.2021
  • Released 07.06.1999
  • Expires For CME 10.06.2024



Historical note and terminology

In 1998 the United States Food and Drug Administration approved modafinil as a wake-promoting agent (to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy). This was the first time in over 40 years such a drug was approved. In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift-work sleep disorder, and idiopathic hypersomnia.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125